Matarin Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Matarin Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-78,279	Closed	-$1.01M	–	292
2019 Q1	$1.01M	Buy	78,279 +16,417	+27%	+$244K	0.07%	208
2018 Q4	$940K	Buy	61,862 +484	+0.8%	+$9.22K	0.08%	204
2018 Q3	$1.23M	Sell	61,378 -1,194	-2%	-$27.2K	0.08%	205
2018 Q2	$1.22M	Buy	+62,572	New	+$1.38M	0.09%	199
2017 Q4	–	Sell	-36,108	Closed	-$666K	–	326
2017 Q3	$666K	Sell	36,108 -339	-0.9%	-$6.32K	0.06%	223
2017 Q2	$671K	Buy	36,447 +2,034	+6%	+$40.3K	0.06%	203
2017 Q1	$776K	Buy	34,413 +17,951	+109%	+$430K	0.08%	205
2016 Q4	$573K	Buy	+16,462	New	+$492K	0.06%	197

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Matarin Capital Management's AMAG Position: Q2 2019 in Review

Matarin Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2019, closing a stake of 78,279 shares — an estimated $1.01M sold.

Matarin Capital Management first reported a position in AMAG in Q4 2016 and held it in 8 quarters. The position peaked at $1.23M in Q3 2018. 170 funds tracked by Wall St. Rank hold AMAG as of Q2 2019.

Matarin Capital Management reported no remaining AMAG Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Matarin Capital Management sold 78,279 AMAG Pharmaceuticals shares in Q2 2019, an estimated $1.01M.
Matarin Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2016 and held it in 8 quarters.
Matarin Capital Management's AMAG Pharmaceuticals position peaked at $1.23M in Q3 2018.
170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2019.

Based on Matarin Capital Management's 13F filing for Q2 2019, filed 8 Aug 2019.